论文部分内容阅读
近日,诺华公布了一项正在进行的Ⅱ期临床研究的数据。研究表明,试验性嵌合抗原受体(CAR)T细胞治疗药物CTL019在治疗特定类型难治性非霍奇金淋巴瘤方面具有潜力。这项由宾夕法尼亚大学佩雷尔曼医学院正在成人复发性或难治性(r/r)弥漫性大B细胞淋巴瘤(DLBCL)和滤泡性淋巴瘤(FL)患者中进行的研究发现,FL患者中的总体应答率(ORR)为100%,DLBCL患者中的ORR为50%。19例可评估患者中有13例对治疗产生应答。11例患者对治疗产生完全应答(CR),2例产生部分应答
Novartis recently released data on an ongoing Phase II clinical study. Studies have shown that the experimental chimeric antigen receptor (CAR) T cell therapy CTL019 has potential in the treatment of specific types of refractory non-Hodgkin’s lymphoma. The study, conducted by Perelman Medical School of the University of Pennsylvania in adults with recurrent or refractory (r / r) diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) The overall response rate (ORR) in FL patients was 100%, and the ORR in DLBCL patients was 50%. Thirteen of the 19 evaluable patients responded to the treatment. Eleven patients had complete response (CR) to treatment and two had partial response